Skip to main content
Premium Trial:

Request an Annual Quote

Biocept: Antonino Morales, Robert Walsh, Samuel Riccitelli

Biocept has named Antonino Morales as president and CEO. He has been the San Diego-based company's interim CFO since February 2022 and a director since July 2021. Samuel Riccitelli, Biocept's interim president and CEO and a director of the firm, has resigned. The company also said that Controller Robert Walsh has been promoted to VP and will serve as principal accounting officer. He will continue as Biocept's controller.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.